within Pharmacolibrary.Drugs.ATC.P;

model P03BX06
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>P03BX06</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Etohexadiol (6,6-dihydroxy-2,4-hexadiene) is an aliphatic alcohol formerly used as an ectoparasiticide and insect repellent, particularly for the control of head lice and mosquitoes. Etohexadiol is no longer approved for human use due to toxicity concerns, primarily neurotoxicity and developmental toxicity identified in animal studies.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for etohexadiol have not been reported in existing peer-reviewed literature or public pharmacokinetic databases for humans, likely due to discontinued clinical use and safety concerns.</p><h4>References</h4><ol><li><p>Ong, RR, &amp; Goh, CF (2024). Niacinamide: a review on dermal delivery strategies and clinical evidence. <i>Drug delivery and translational research</i> 14(12) 3512–3548. DOI:<a href=\"https://doi.org/10.1007/s13346-024-01593-y\">10.1007/s13346-024-01593-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38722460/\">https://pubmed.ncbi.nlm.nih.gov/38722460</a></p></li><li><p>Gorouhi, F, &amp; Maibach, HI (2009). Role of topical peptides in preventing or treating aged skin. <i>International journal of cosmetic science</i> 31(5) 327–345. DOI:<a href=\"https://doi.org/10.1111/j.1468-2494.2009.00490.x\">10.1111/j.1468-2494.2009.00490.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19570099/\">https://pubmed.ncbi.nlm.nih.gov/19570099</a></p></li><li><p>Irvine, J, Afrose, A, &amp; Islam, N (2018). Formulation and delivery strategies of ibuprofen: challenges and opportunities. <i>Drug development and industrial pharmacy</i> 44(2) 173–183. DOI:<a href=\"https://doi.org/10.1080/03639045.2017.1391838\">10.1080/03639045.2017.1391838</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29022772/\">https://pubmed.ncbi.nlm.nih.gov/29022772</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end P03BX06;
